For CVD, additive therapies are tied to reduced mortality, costs

  • Institute for Clinical and Economic Review

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Adding rivaroxaban (Xarelto) or icosapent ethyl (IE) to aspirin or statins, respectively, for patients with cardiovascular disease (CVD) offers a “small-to-substantial” health benefit in terms of reduced mortality.
  • These additions also offer cost-effectiveness, according to analysis from the Institute for Clinical and Economic Review.

Why this matters

  • Optimizing treatment while avoiding high costs is an ongoing struggle.

Key results

  • For patients with stable CVD, adding rivaroxaban to aspirin is tied to reduced cardiovascular death, stroke, myocardial infarction, with a significant increase in the most severe bleeding events.
    • These authors concluded with “high certainty” that this addition would provide a “small-to-substantial” net health benefit for patients with CVD, peripheral artery disease, or both.
    • They could not confidently determine how the combination compared with dual antiplatelet therapy because data were insufficient.
  • IE added some benefit vs optimal medical management alone for patients with established CVD or diabetes mellitus and further risk factors who are taking statins.
    • These authors had “high certainty” of a “small-to-substantial” benefit with this addition.
  • Both additions fell within cost-effectiveness thresholds. 

Study design

  • This group modeled these additions vs comparators in terms of patient survival, quality-adjusted survival, and health care costs.
  • Funding: Laura and John Arnold Foundation; others.

Limitations

  • Other cardiovascular events not considered.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit